Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Open access

Abstract

RAS mutations are frequent in human cancer, especially in pancreatic, colorectal and non-small-cell lung cancers (NSCLCs)1-3. Inhibition of the RAS oncoproteins has proven difficult 4, and attempts to target downstream effectors 5-7 have been hampered by the activation of compensatory resistance mechanisms 8. It is also well established that KRAS-mutant tumors are insensitive to inhibition of upstream growth factor receptor signaling. Thus, epidermal growth factor receptor antibody therapy is only effective in KRAS wild-type colon cancers 9,10. Consistently, inhibition of SHP2 (also known as PTPN11), which links receptor tyrosine kinase signaling to the RAS-RAF-MEK-ERK pathway 11,12, was shown to be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines 13. Our data also indicate that SHP2 inhibition in KRAS-mutant NSCLC cells under normal cell culture conditions has little effect. By contrast, SHP2 inhibition under growth factor-limiting conditions in vitro results in a senescence response. In vivo, inhibition of SHP2 in KRAS-mutant NSCLC also provokes a senescence response, which is exacerbated by MEK inhibition. Our data identify SHP2 inhibition as an unexpected vulnerability of KRAS-mutant NSCLC cells that remains undetected in cell culture and can be exploited therapeutically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0023-9

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

9 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 330

Metadata

Authors
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., Nadal, E., Bardelli, A., Villanueva, A., & Bernards, R.
Affiliations
  • The Netherlands Cancer Institute (NL)
  • Novartis (Switzerland) (CH)
  • Candiolo Cancer Institute (IT)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Institut Català d'Oncologia (ES)
Venue
Nature Medicine
Published
2018-05-28
Volume
24
Issue
7
Pages
961-967
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2804804971
Cited by
320
References
38
Citations by year
2026: 24 · 2025: 19 · 2024: 36 · 2023: 41 · 2022: 52 · 2021: 53 · 2020: 49 · 2019: 31 · 2018: 15
FWCI
13.27
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.springer.com/tdm (tdm)
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
SHP2, PTPN11, KRAS mutation, non-small cell lung cancer, Ras signaling, MEK inhibition, cellular senescence, combination therapy, RAS/MAPK pathway, growth factor receptor signaling, therapeutic target
MeSH terms
Animals, Carcinoma, Non-Small-Cell Lung, Guanosine Triphosphate, Humans, Lung Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), Cellular Senescence, Mitogen-Activated Protein Kinase Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. https://app.cochat.ai/papers/10.1038/s41591-018-0023-9
The paper
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., Nadal, E., Bardelli, A., Villanueva, A., & Bernards, R. (2018). SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. Nature Medicine. https://doi.org/10.1038/s41591-018-0023-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.